Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Date
2021
Author
Varkonyi, Judit
Sperr, Wolfgang R.
Kluin-Nelemans, Hanneke C.
Jawhar, Mohamad
Reiter, Andreas
van Anrooij, Bjorn
Gotlib, Jason
Hartmann, Karin
Illerhaus, Anja
Elberink, Hanneke N. G. Oude
Gorska, Aleksandra
Niedoszytko, Marek
Hermine, Olivier
Rossignol, Julien
Arock, Michel
Lange, Magdalena
Scaffidi, Luigi
Zanotti, Roberta
Bonadonna, Patrizia
Perkins, Cecelia
Elena, Chiara
Malcovati, Luca
Shoumariyeh, Khalid
von Bubnoff, Nikolas
Mueller, Sabine
Triggiani, Massimo
Parente, Roberta
Schwaab, Juliana
Kundi, Michael
Fortina, Anna Belloni
Caroppo, Francesca
Brockow, Knut
Zink, Alexander
Fuchs, David
Angelova-Fischer, Irena
Yavuz, Akif
Doubek, Michael
Mattsson, Mattias
Hagglund, Hans
Panse, Jens
Simonowski, Anne
Sabato, Vito
Schug, Tanja
Jentzsch, Madlen
Breynaert, Christine
Valent, Peter
Kennedy, Vanessa
Metadata
Show full item record
Abstract
In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown.
URI
http://hdl.handle.net/20.500.12627/1691
https://doi.org/10.7150/thno.51872
Collections